1. Home
  2. DNN vs VRDN Comparison

DNN vs VRDN Comparison

Compare DNN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Denison Mines Corp (Canada)

DNN

Denison Mines Corp (Canada)

N/A

Current Price

$2.21

Market Cap

2.3B

ML Signal

N/A

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

N/A

Current Price

$24.57

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DNN
VRDN
Founded
1954
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.1B
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
DNN
VRDN
Price
$2.21
$24.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
17
Target Price
$4.73
★ $36.20
AVG Volume (30 Days)
★ 26.8M
2.0M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $5,706,000.00
Revenue This Year
$321.58
N/A
Revenue Next Year
$38.26
$878.45
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.10
$13.18
52 Week High
$4.43
$34.29

Technical Indicators

Market Signals
Indicator
DNN
VRDN
Relative Strength Index (RSI) 36.99 68.17
Support Level $2.10 $21.40
Resistance Level $3.43 $24.86
Average True Range (ATR) 0.12 1.00
MACD 0.03 0.57
Stochastic Oscillator 23.44 88.72

Price Performance

Historical Comparison
DNN
VRDN

About DNN Denison Mines Corp (Canada)

Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: